Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2010 3
2011 6
2012 3
2013 5
2014 5
2015 13
2016 23
2017 16
2018 16
2019 10
2020 6
2021 5
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Necitumumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999841 Free Books & Documents. Review.
No information is available on the clinical use of necitumumab during breastfeeding. Because necitumumab is a large protein molecule with a molecular weight of 145,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in …
No information is available on the clinical use of necitumumab during breastfeeding. Because necitumumab is a large protein mo …
Necitumumab.
[No authors listed] [No authors listed] 2017 May 29. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 May 29. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643800 Free Books & Documents. Review.
Necitumumab is a human monoclonal antibody to the epidermal growth factor (EGF) receptor and is an anti-angiogenesis agent used in the therapy of advanced non-small cell lung cancer. Necitumumab has not been linked to serum enzyme elevations during therapy or to idi …
Necitumumab is a human monoclonal antibody to the epidermal growth factor (EGF) receptor and is an anti-angiogenesis agent used in th …
Necitumumab for the treatment of advanced non-small-cell lung cancer.
Díaz-Serrano A, Sánchez-Torre A, Paz-Ares L. Díaz-Serrano A, et al. Future Oncol. 2019 Mar;15(7):705-716. doi: 10.2217/fon-2018-0594. Epub 2018 Dec 3. Future Oncol. 2019. PMID: 30501503 Review.
The EGFR pathway has been explored as a druggable target with monoclonal antibodies such as cetuximab or necitumumab. Necitumumab is a humanized IgG1 anti-EGFR. In the Phase III SQUIRE trial, necitumumab used as first-line therapy in combination with cisplati …
The EGFR pathway has been explored as a druggable target with monoclonal antibodies such as cetuximab or necitumumab. Necitumumab …
Necitumumab for the treatment of squamous cell non-small cell lung cancer.
Brinkmeyer JK, Moore DC. Brinkmeyer JK, et al. J Oncol Pharm Pract. 2018 Jan;24(1):37-41. doi: 10.1177/1078155216682365. Epub 2016 Dec 2. J Oncol Pharm Pract. 2018. PMID: 27913776 Review.
Necitumumab is associated with adverse events such as infusion reactions, hypomagnesemia, diarrhea, and dermatological toxicities. ...Several clinical trials are ongoing in order to further investigate the utilization of necitumumab....
Necitumumab is associated with adverse events such as infusion reactions, hypomagnesemia, diarrhea, and dermatological toxicities. .. …
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
di Noia V, D'Argento E, Pilotto S, Grizzi G, Caccese M, Iacovelli R, Tortora G, Bria E. di Noia V, et al. Expert Opin Biol Ther. 2018 Sep;18(9):937-945. doi: 10.1080/14712598.2018.1508445. Epub 2018 Aug 9. Expert Opin Biol Ther. 2018. PMID: 30075697 Review.
Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Necitumumab is a fully humanized IgG1 monoclonal antibody directed against …
Over the last decade, epidermal growth factor receptor (EGFR) signaling was investigated as a potential target for tyrosine kinase inhibitor …
Necitumumab: First Global Approval.
Garnock-Jones KP. Garnock-Jones KP. Drugs. 2016 Feb;76(2):283-9. doi: 10.1007/s40265-015-0537-0. Drugs. 2016. PMID: 26729188 Review.
Necitumumab was derived from the proprietary phage display library of Dyax Corp, and originated with ImClone Systems, which was acquired by Eli Lilly in November 2008. Necitumumab was also under phase II development for colorectal cancer in Belgium and Spain; howeve …
Necitumumab was derived from the proprietary phage display library of Dyax Corp, and originated with ImClone Systems, which was acqui …
Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E, Zugazagoitia Fraile J, Paz-Ares Rodríguez L. Jiménez Aguilar E, et al. Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):765-772. doi: 10.1080/17425255.2018.1498839. Epub 2018 Jul 31. Expert Opin Drug Metab Toxicol. 2018. PMID: 30025476 Review.
The phase III SQUIRE trial was a randomized study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone for first-line stage IV squamous NSCLC, showing a higher overall survival and better disease control with the addition of necitumumab. Desp …
The phase III SQUIRE trial was a randomized study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone for fi …
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma.
Thakur MK, Wozniak AJ. Thakur MK, et al. Lung Cancer (Auckl). 2017 Feb 13;8:13-19. doi: 10.2147/LCTT.S104207. eCollection 2017. Lung Cancer (Auckl). 2017. PMID: 28293124 Free PMC article. Review.
Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitumumab is a second-generation fully human IgG1 monoclonal antibody that has shown promise in metastatic NSCLC. ...This review focuses on t …
Monoclonal antibodies have also been developed that block the EGFR at the cell surface and work in conjunction with chemotherapy. Necitum …
Necitumumab for non-small cell lung cancer.
Greillier L, Tomasini P, Barlesi F. Greillier L, et al. Expert Opin Biol Ther. 2015;15(8):1231-9. doi: 10.1517/14712598.2015.1055243. Epub 2015 Jun 8. Expert Opin Biol Ther. 2015. PMID: 26051700 Review.
INTRODUCTION: Targeting the EGFR pathway is a rational approach to treat patients with advanced NSCLC. Necitumumab, a second-generation recombinant fully human immunoglobulin G1 monoclonal antibody directed against EGFR, has recently been assessed in combination with first …
INTRODUCTION: Targeting the EGFR pathway is a rational approach to treat patients with advanced NSCLC. Necitumumab, a second-generati …
Clinical potential of necitumumab in non-small cell lung carcinoma.
Genova C, Hirsch FR. Genova C, et al. Onco Targets Ther. 2016 Aug 31;9:5427-37. doi: 10.2147/OTT.S114039. eCollection 2016. Onco Targets Ther. 2016. PMID: 27621656 Free PMC article. Review.
Although EGFR mutations are more frequent in non-squamous histology, the receptor itself is more often overexpressed in squamous NSCLC. Necitumumab is a human monoclonal antibody that is able to inhibit the EGFR pathway and cause antibody-dependent cell cytotoxicity. ...Th …
Although EGFR mutations are more frequent in non-squamous histology, the receptor itself is more often overexpressed in squamous NSCLC. N …
102 results